Indo Borax Q1 FY27: Revenue ₹70.36 Cr, PAT ₹16.25 Cr; Acquires Kronox Lab Sciences
Indo Borax & Chemicals reported Q1 FY27 consolidated revenue of ₹70.36 Cr, up 31.34% YoY, with PAT at ₹16.25 Cr, up 59.31% YoY. The company approved the acquisition of 64.26% of Kronox Lab Sciences for ₹246.12 Cr. An amalgamation of its subsidiary was also approved.
The significant financial performance improvement and the material strategic acquisition of Kronox Lab Sciences, along with the internal restructuring through amalgamation, are expected to have a substantial impact on the company's future operations, market position, and financial performance.
The company reported strong year-over-year growth in revenue, EBITDA, and net profit for Q1 FY27. The strategic acquisition of Kronox Lab Sciences and the approved amalgamation of its subsidiary are positive developments that are expected to drive future growth and efficiency.
Indo Borax & Chemicals Limited has announced its financial results for the quarter ended June 30, 2026 (Q1 FY27). The company reported a consolidated operating revenue of ₹70.36 crore, marking a 31.34% year-over-year increase. EBITDA rose by 62.16% YoY to ₹19.80 crore, with an improved EBITDA margin of 28.14%. Net profit saw a significant jump of 59.31% YoY to ₹16.25 crore, resulting in an Earnings Per Share (EPS) of ₹5.07.
The strong performance was attributed to improved capacity utilization, operational efficiencies, and higher product realizations, supported by steady domestic demand.
In a significant post-quarter development, the Board of Directors approved the amalgamation of its wholly-owned subsidiary, Indoborax Infrastructure Private Limited, with Indo Borax & Chemicals Ltd. This move aims to enhance efficiency and streamline governance.
Furthermore, the company announced the acquisition of 64.26% equity shares of Kronox Lab Sciences for ₹246.12 crore. Indo Borax also plans to make an Open Offer for an additional 25.79% stake in Kronox Lab Sciences. This strategic acquisition is expected to leverage Kronox's expertise and export presence, strengthen product offerings, and improve margins through synergies. Kronox Lab Sciences reported a revenue of ₹101 crore and a PAT of approximately ₹28 crore in FY26.
The company also provided an update on its investor presentation for the earnings call scheduled for September 02, 2026, at 4:00 p.m. IST, to discuss the Unaudited Financial Results for Q1 FY27.
A plain-language summary of a public exchange filing by Indo Borax & Chemicals Limited. Read the original for the full detail.